MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Compared with placebo, ATH434 demonstrated a statistically significant 48% slowing of clinical progression (based on UMSARS score) at the 50mg dose at week 52. The Food and Drug Administration (FDA) ...
The Swoop portable MRI system showed 92% agreement with traditional MRI scans and was four times more likely to be chosen by ...
MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
A new study by the University of Turku and Turku University Hospital, Finland, found that a significant proportion of Parkinson's disease diagnoses are later corrected. Up to one in six diagnoses ...
MELBOURNE, Australia and SAN FRANCISCO, July 28, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying ...
α-synuclein is a neuronal protein involved in functions like vesicle trafficking and neurotransmitter release. It is typically found in abundance in a healthy brain. However, the aggregation of ...
Cytora Reports Phase 1 Data of Stem Cell Treatment for Multiple System Atrophy Cytora Reports Phase 1 Data of Stem Cell Treatment for Multiple System Atrophy PR Newswire YOKNEAM, Israel, May 19, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results